

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| Concentration | Treated Time | Description | References | |
| HEK293T cells | 5 nM | 6 hours | Erianin directly bound to NLRP3, inhibiting its ATPase activity and thereby blocking NLRP3 inflammasome assembly. | Front Immunol. 2021 Oct 20;12:739953. |
| THP-1 cells | 5 nM | 6 hours | Erianin suppressed NLRP3 inflammasome activation by preventing NEK7-NLRP3 and ASC-NLRP3 interactions. | Front Immunol. 2021 Oct 20;12:739953. |
| HCT116 (KRAS mutant) | 12.5, 25, 50 nM | 24 hours | Inhibited constitutive activation of MAPK signaling pathway | Signal Transduct Target Ther. 2023 Mar 6;8(1):96. |
| A375 (BRAF V600E mutant) | 12.5, 25, 50 nM | 24 hours | Inhibited constitutive activation of MAPK signaling pathway | Signal Transduct Target Ther. 2023 Mar 6;8(1):96. |
| SK-MEL-2 (NRAS mutant) | 12.5, 25, 50 nM | 24 hours | Inhibited constitutive activation of MAPK signaling pathway | Signal Transduct Target Ther. 2023 Mar 6;8(1):96. |
| MG63.2 cells | 0, 10, 25, 50, 100 nM | 24, 48, 72 hours | Erianin inhibited the proliferation of MG63.2 cells in a time and dose-dependent manner with IC50 values of 88.69 nM (24 h), 44.26 nM (48 h), and 17.20 nM (72 h). | Cell Death Dis. 2016 Jun 2;7(6):e2247. |
| 143B cells | 0, 10, 25, 50, 100 nM | 24, 48, 72 hours | Erianin inhibited the proliferation of 143B cells in a time and dose-dependent manner with IC50 values of 58.19 nM (24 h), 40.97 nM (48 h), and 26.77 nM (72 h). | Cell Death Dis. 2016 Jun 2;7(6):e2247. |
| NCI-H1299 (H1299) | 200, 100, 50, 25, 12.5, and 0 nM | 24 hours | To evaluate the effect of Erianin on lung cancer cell viability. Erianin significantly reduced the survival rate of both cell lines, with IC50 values of 61.33 nM for H460 cells and 21.89 nM for H1299 cells. | Cancer Biol Med. 2025 Feb 24;22(2):144–65. |
| NCI-H460 (H460) | 200, 100, 50, 25, 12.5, and 0 nM | 24 hours | To evaluate the effect of Erianin on lung cancer cell viability. Erianin significantly reduced the survival rate of both cell lines, with IC50 values of 61.33 nM for H460 cells and 21.89 nM for H1299 cells. | Cancer Biol Med. 2025 Feb 24;22(2):144–65. |
| Human immortalized keratinocyte (HaCaT) | 30 nM | 24 hours | To evaluate the anti-proliferative and pro-apoptotic effects of E/DMSNs on HaCaT cells. Results showed that E/DMSNs had stronger anti-proliferative and pro-apoptotic effects than free erianin. | J Nanobiotechnology. 2020 Mar 30;18(1):55. |
| Human Retinal Vascular Endothelial Cells (HRVECs) | 10-100 nM | 24 hours | Erianin significantly inhibited the proliferation, migration, tube formation, and adhesion of hypoxia-induced HRVECs in a concentration-dependent manner. The inhibitory effect on cell proliferation and tube formation was more pronounced in the collagen-cultured group. | Invest Ophthalmol Vis Sci. 2022 Jan 3;63(1):27. |
| Administration | Dosage | Frequency | Description | References | ||
| C57BL/6 mice | MSU-induced peritonitis and gouty arthritis models | Intraperitoneal injection | 5 mg/kg | Single injection, lasting 12 hours | Erianin exhibited dose-dependent inhibitory effects on MSU-induced IL-1β and IL-18 production and neutrophil migration but had no effect on TNF-α production. | Front Immunol. 2021 Oct 20;12:739953. |
| NOD-SCID mice | A375 (BRAF V600E mutant) and SK-MEL-2 (NRAS mutant) cell-derived xenograft model | Oral gavage | 50 mg/kg | Once daily, tumor volume was monitored twice per week | Inhibited tumor growth and reduced tumor volume and weight | Signal Transduct Target Ther. 2023 Mar 6;8(1):96. |
| BALB/c nude mice | H460 cell xenograft model | Intraperitoneal injection | 100 mg/kg | Once daily for 15 days | Erianin notably suppressed tumor growth | Signal Transduct Target Ther. 2020 May 8;5(1):51 |
| BALB/c-nu mice | Osteosarcoma xenograft model | Intraperitoneal injection | 2 mg/kg | Every other day for seven times | Erianin significantly inhibited tumor growth with little organ-related toxicity. | Cell Death Dis. 2016 Jun 2;7(6):e2247. |
| Nude mice | Lung cancer-bearing nude mice model | Intraperitoneal injection | 50 mg/kg, 100 mg/kg, and 200 mg/kg | Every 2nd day for 18 days | To evaluate the inhibitory effects of Erianin on lung cancer growth in vivo. Medium and high doses of Erianin significantly inhibited tumor growth without significant effects on body weight. | Cancer Biol Med. 2025 Feb 24;22(2):144–65. |
| Zebrafish (adult and embryos) | Hypoxia-induced retinopathy model | Embryo medium (embryo model) and intravitreal injection (adult model) | 100-1000 nM | Embryo model: 4 days; Adult model: 7 days | Erianin significantly reduced hypoxia-induced retinal angiogenesis in zebrafish in a concentration-dependent manner. In the adult model, the inhibitory effects on vascular branch points, sprouts, and vascularization areas were more pronounced. | Invest Ophthalmol Vis Sci. 2022 Jan 3;63(1):27. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.14mL 0.63mL 0.31mL |
15.71mL 3.14mL 1.57mL |
31.41mL 6.28mL 3.14mL |
|
| CAS号 | 95041-90-0 |
| 分子式 | C18H22O5 |
| 分子量 | 318.36 |
| SMILES Code | COC1=C(C=C(C=C1)CCC2=CC(OC)=C(C(OC)=C2)OC)O |
| MDL No. | MFCD06795132 |
| 别名 | NSC 613744 |
| 运输 | 蓝冰 |
| InChI Key | UXDFUVFNIAJEGM-UHFFFAOYSA-N |
| Pubchem ID | 356759 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place,Inert atmosphere,2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(329.81 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1